Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models
Eur Urol. 2017 Sep;72(3):e70-e71.
doi: 10.1016/j.eururo.2017.04.031.
Epub 2017 May 9.
1 Turku Centre for Biotechnology, Turku, Finland; Department of Mathematics and Statistics, University of Turku, Turku, Finland.
2 Turku Centre for Biotechnology, Turku, Finland; Department of Information Technology, University of Turku, Turku, Finland.
3 Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland.
4 Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland; Department of Clinical Oncology, University of Turku, Turku, Finland.
5 Department of Pulmonary Diseases and Clinical Allergology, Turku University Hospital and University of Turku, Turku, Finland; Centre for Clinical Informatics, Turku University Hospital, Turku, Finland.
6 Turku Centre for Biotechnology, Turku, Finland. Electronic address: laura.elo@utu.fi.